ALK and non-small cell lung carcinoma: Molecular testing for epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements have become standard diagnostic procedures in the management of NSCLC.38, 39 DNA mutations in the EGFR gene, as detected by polymerase chain reaction (PCR), may occur in regions corresponding to the extracellular or the intracellular portions of the EGFR protein.